Cost-effectiveness of losartan in patients with hypertension and LVH in Spain: An economic evaluation based on the life trial

被引：1

作者：

Ruilope, LM

Burke, TA

Carides, GW

Nocea, G

机构：

[1] Hosp 12 Octubre, E-28041 Madrid, Spain

[2] Merck & Co Inc, Whitehouse Stn, NJ USA

[3] Merck Res Labs, Blue Bell, PA USA

[4] MSD Spain, Madrid, Spain

来源：

VALUE IN HEALTH | 2004年 / 7卷 / 06期

关键词：

D O I：

10.1016/S1098-3015(10)65797-X

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：689 / 689

页数：1

共 50 条

[1] Cost-effectiveness of losartan in patients with hypertension and LVH: An economic evaluation of the LIFE trial
Jonsson, B
Carides, GW
Burke, TA
Dasbach, EJ
Lindholm, L
Dahlof, B
JOURNAL OF HYPERTENSION, 2004, 22 : S289 - S290
[2] Cost effectiveness of losartan in patients with hypertension and LVH:: an economic evaluation for Sweden of the LIFE trial
Jönsson, B
Carides, GW
Burke, TA
Dasbach, LJ
Lindholm, LH
Dahlöf, B
JOURNAL OF HYPERTENSION, 2005, 23 (07) : 1425 - 1431
[3] Cost-effectiveness of losartan in patients with hypertension and LVH: An economic evaluation for the Netherlands based on the LIFE-study
Boersma, C
Carides, GW
Burke, TA
Postma, MJ
VALUE IN HEALTH, 2005, 8 (06) : A150 - A151
[4] Cost-effectiveness of losartan in patients with hypertension and LVH: An economic evaluation for the Netherlands based on the LIFE-study
Boersma, C.
Carides, G. W.
Postma, M. J.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (06) : 720 - 721
[5] Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study
McInnes, G
Burke, TA
Carides, G
JOURNAL OF HUMAN HYPERTENSION, 2006, 20 (01) : 51 - 58
[6] Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study
G McInnes
T A Burke
G Carides
Journal of Human Hypertension, 2006, 20 : 51 - 58
[7] Cost-effectiveness of losartan in patients with hypertension and left ventricular hypertrophy: cost per quality-adjusted life years gained in the LIFE trial
Jonsson, B
Carides, GW
Burke, TA
Dasbach, EJ
Lindholm, LH
Dahlof, B
EUROPEAN HEART JOURNAL, 2004, 25 : 331 - 331
[8] Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden
Ekman, M.
Bienfait-Beuzon, C.
Jackson, J.
JOURNAL OF HUMAN HYPERTENSION, 2008, 22 (12) : 845 - 855
[9] Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden
M Ekman
C Bienfait-Beuzon
J Jackson
Journal of Human Hypertension, 2008, 22 : 845 - 855
[10] An economic evaluation of intensive hypertension control in CKD patients: a cost-effectiveness study
Ye Seol Lee
Hae-Young Lee
Tae Hyun Kim
Clinical Hypertension, 28

← 1 2 3 4 5 →